Acta Scientific Cancer Biology

Case ReportVolume 2 Issue 4

Targeted Therapies in EGFR and ALK Wild Type Advanced NSCLC in an Elderly Patient

Ruchir Tandon*

Jaypee Hospital, India

*Corresponding Author: Ruchir Tandon, Jaypee Hospital, India.

Received: May 08, 2018; Published: May 28, 2018

Citation: Ruchir Tandon. “Targeted Therapies in EGFR and ALK Wild Type Advanced NSCLC in an Elderly Patient". Acta Scientific Cancer Biology 2.5 (2018).

Abstract

  Adenocarcinoma variants of NSCLC often present without an activating EGFR mutation or ALK translocation. In unresectable stage III Guidelines recommend definitive concurrent chemoradiotherapy or induction chemotherapy with platinum-based doublet chemotherapy followed by Radiotherapy. Patient’s performance status, age, issues of toxicity, convenience and acceptability should be seen while selecting the appropriate therapy for an individual patient. EGFR TKIs show promising results even in EGFR wild type cases.

Keywords: Adenocarcinoma (NSCLC); EGFR Wild Type; Afatinib

Copyright: © 2018 Ruchir Tandon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Member In



News and Events


  • Submission Timeline for Regular Issue
    Last date for submission of articles for regular Issues is October 30, 2019.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US